Search | Clinical Trials Finder

Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myeloid Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
Interventions: Anti-thymocyte globulin (rabbit), Blinatumomab, Cyclophosphamide, Fludarabine, G-CSF, Melphalan, Mesna, Rituximab, Tacrolimus, Thiotepa, HPC,A Infusion, CliniMACS, Sirolimus; Drug · Biological · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome
Interventions: Clofarabine/Busulfan x 4, Peripheral blood stem cell transplant, Total Lymphoid Irradiation; Drug · Procedure · Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: Up to 70 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hematologic Malignancies
Interventions: Busulfan 3.2 mg/kg/day, Fludarabine, Melphalan, Antithymocyte globulin (ATG), Busulfan 0.8 mg/kg, Allogeneic hematopoietic cell transplantation (Allo-HCT); Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions: Busulfan, Clofarabine, Allogeneic Stem Cell Infusion; Drug · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
Interventions: Rituximab, Rabbit ATG, Cyclophosphamide, Fludarabine, Total Body Irradiation, Cell Infusion, Post-Transplant G-CSF, Tacrolimus, Mycophenolate Mofetil; Drug · Radiation · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 0 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2036
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Placebo Effect, Pain
Interventions: Observed Success, Observed Failure, Experienced Success, Experienced Failure; Behavioral
Lead sponsor: Trustees of Dartmouth College; Other
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Hanover, New Hampshire

Conditions: Healthy Volunteers
Interventions: High Intensity Exercise, Low Intensity Exercise, High Carbohydrate Beverage, High Fat Beverage; Other
Lead sponsor: USDA Beltsville Human Nutrition Research Center; Federal
Eligibility: 22 Years to 35 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Beltsville, Maryland

Conditions: Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Chronic Lymphocytic Leukemia
Interventions: Plerixafor; Drug
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 18 Years to 65 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 9 more

Conditions: Dental Caries
Interventions: Ketac Universal, Ketac Molar Quick; Device
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 12 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Hypertrophy
Interventions: Resistance Exercise, Whole Eggs, Egg Whites; Behavioral · Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Polycystic Ovary Syndrome
Interventions: Metformin, Dietary Restriction, Exercise Training; Drug · Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Carbohydrate Metabolism
Interventions: CS- Beverage, CS+Fast, CS+Slow; Other
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53, Intrachromosomal Amplification of Chromosome 21, Cytogenetic Abnormality, CNS Leukemia, Minimal Residual Disease, Myelodysplasia, Juvenile Myelomonocytic Leukemia, Somatic Mutation, PTPN11 Gene Mutation, N-RAS Gene Amplification, Neurofibromatosis 1, NF1 Mutation, CBL Gene Mutation, Monosomy 7, Chromosome Abnormality, Fetal Hemoglobin, Lymphoblastic Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult
Interventions: Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam, Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells, Thymoglobulin, Cyclophosphamide; Drug · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 60 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Spinal Cord Injuries, Tetraplegia, Paraplegia, Muscle Loss, Atrophy, Muscular, Insulin Resistance
Interventions: Ursolic Acid, Strength Training; Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer
Interventions: Resistance Exercise, Aerobic Exercise, Behavioral Group Counseling; Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Acute Migraine
Interventions: Nerivio; Device
Lead sponsor: Theranica; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 12
States / cities: Aurora, Colorado • Hialeah, Florida • Miami, Florida + 8 more

Conditions: Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myelodysplastic Syndrome Other, Chronic Myelomonocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Interventions: Cyclophosphamide, Fludarabine, Thiotepa, Total Body Irradiation, Double Umbilical Cord Transplant, Tacrolimus, Mycophenolate Mofetil, Abatacept; Drug · Radiation · Biological
Lead sponsor: Leland Metheny; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma
Interventions: Daratumumab; Drug
Lead sponsor: New York Medical College; Other
Eligibility: Up to 39 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 16
States / cities: Phoeniz, Arizona • Loma Linda, California • Los Angeles, California + 13 more

Conditions: HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: 18F-FHBG, Aldesleukin, Cellular Therapy, Computed Tomography, Filgrastim, Laboratory Biomarker Analysis, Lenalidomide, Leukapheresis, Melphalan, Plerixafor, Positron Emission Tomography; Radiation · Biological · Procedure + 2 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Aging
Interventions: Aerobic Exercise, Non-Aerobic Exercise; Behavioral
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lower Limb Amputation Above Knee, Below Knee Amputation
Interventions: Blood pressure cuff, Neuromuscular Electrical Stimulation; Device
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Myelodysplastic Syndrome, Myeloproliferative Neoplasms, Chronic Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Myelodysplastic/Myeloproliferative Overlapping Syndrome
Interventions: Geriatric assessment (GA) pre-transplant, conditioning regimen, Allogeneic CD34+ selected stem cells; Other · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Aplastic Anemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Marrow Transplantation, Computed Tomography, Cyclosporine, Fludarabine, Granulocyte Colony-Stimulating Factor, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Ruxolitinib, Sirolimus, Total-Body Irradiation, Multigated Acquisition Scan, Echocardiography; Procedure · Drug · Radiation
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Muscle Protein Synthetic Response to Protein, Muscle Protein Synthesis, Muscle Health, Protein Metabolism, Recreational Activities, Isotope Labeling
Interventions: Resistance Exercise, Potato and Beef, Bread and Beef, Beef; Behavioral · Dietary Supplement
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 19 Years to 40 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Urbana, Illinois

Search by objective public record fields.

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen

Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation

Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Context Interventions: Social Modeling and Initial Treatment Experience

Metabolic Flexibility as a Biomarker of Adaptation to Diet and Exercise Challenges

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Clinical Performance of Posterior Glass Ionomer Restorations in Adolescents (KETAC)

Muscle Protein Synthesis After Whole Egg vs. Egg White Consumption

Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS

Neural and Metabolic Factors in Carbohydrate Reward

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)

Exercising Our ABC's (African- American Breast Cancer Survivors)

Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

Neuroimaging Study of Exercise and Memory Function

Determining the Effects of Ischemic Conditioning and Neuromuscular Electrical Stimulation on Overall Function After Lower Limb Amputation

Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders

Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

Diet Synergy in Muscle Protein Synthesis